Your browser doesn't support javascript.
loading
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data.
Coles, Alasdair J; Jones, Joanne L; Vermersch, Patrick; Traboulsee, Anthony; Bass, Ann D; Boster, Aaron; Chan, Andrew; Comi, Giancarlo; Fernández, Óscar; Giovannoni, Gavin; Kubala Havrdova, Eva; LaGanke, Christopher; Montalban, Xavier; Oreja-Guevara, Celia; Piehl, Fredrik; Wiendl, Heinz; Ziemssen, Tjalf.
Affiliation
  • Coles AJ; Department of Clinical Neuroscience, School of Medicine, University of Cambridge, Cambridge, UK.
  • Jones JL; Department of Clinical Neuroscience, School of Medicine, University of Cambridge, Cambridge, UK.
  • Vermersch P; Univ. Lille, INSERM UMR-S1172-Lille Neuroscience et Cognition, CHU Lille, FHU Precise, Lille, France.
  • Traboulsee A; The University of British Columbia, Vancouver, BC, Canada.
  • Bass AD; Neurology Center of San Antonio, San Antonio, TX, USA.
  • Boster A; Boster MS Center, Columbus, OH, USA.
  • Chan A; Bern University Hospital and University of Bern, Bern, Switzerland.
  • Comi G; Università Vita Salute San Raffaele, Milan, Italy.
  • Fernández Ó; Fundacion IMABIS, Hospital Universitario Carlos Haya, Málaga, Spain.
  • Giovannoni G; Barts and The London School of Medicine, Queen Mary University of London, London, UK.
  • Kubala Havrdova E; Department of Neurology, First Medical Faculty, Charles University, Prague, Czech Republic.
  • LaGanke C; North Central Neurology Associates, Cullman, AL, USA.
  • Montalban X; Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Oreja-Guevara C; Department of Neurology, Hospital Clínico San Carlos, IdISSC, Madrid, Spain/Departamento de Medicina, Facultad de Medicina, Universidad Complutense de Madrid (UCM), Madrid, Spain.
  • Piehl F; Neuroimmunology Unit, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Wiendl H; University of Münster, Münster, Germany.
  • Ziemssen T; Center of Clinical Neuroscience, Department of Neurology Carl Gustav Carus University Hospital, Dresden University of Technology, Dresden, Germany.
Mult Scler ; 28(5): 842-846, 2022 04.
Article in En | MEDLINE | ID: mdl-34882037
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Sclerosis, Relapsing-Remitting / Multiple Sclerosis Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Mult Scler Journal subject: NEUROLOGIA Year: 2022 Type: Article Affiliation country: United kingdom
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Multiple Sclerosis, Relapsing-Remitting / Multiple Sclerosis Type of study: Etiology_studies / Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: Mult Scler Journal subject: NEUROLOGIA Year: 2022 Type: Article Affiliation country: United kingdom